Synthesis and evaluation of N-isopropyl-p-[(11)C]methylamphetamine as a novel cerebral blood flow tracer for positron emission tomography

INTRODUCTION: Increases in fasting plasma glucose (PG) levels lead to a decrease in 2-deoxy-2-[(18)F]fluoro-d-glucose ([(18)F]FDG) uptake in the normal brain, especially in the precuneus, resulting in an Alzheimer’s disease (AD)-like uptake pattern. Therefore, patients with higher PG levels, such as those with diabetes, can be erroneously diagnosed with AD when positron emission tomography (PET) imaging is done using [(18)F]FDG, due to reduced uptake of [(18)F]FDG in the precuneus. To help avoid an erroneous diagnosis of AD due to differences in glucose metabolism, evaluating cerebral blood flow (CBF) in the brain is useful. However, current techniques such as single photon emission computed tomography (SPECT) and [(15)O]H(2)O PET have limitations regarding early diagnosis of AD because the images they produce are of low resolution. Here, we developed a novel CBF PET tracer that may be more useful than [(18)F]FDG for diagnosis of AD. METHODS: We synthesized and evaluated N-isopropyl-p-[(11)C]methylamphetamine ([(11)C]4) as a carbon-11-labeled analogue of the standard CBF SPECT tracer N-isopropyl-p-[(123)I]iodoamphetamine. Fundamental biological evaluations such as biodistribution, peripheral metabolism in mice, and brain kinetics of [(11)C]4 in non-human primates with PET with successive measurement of [(15)O]H(2)O were performed. RESULTS: [(11)C]4 was synthesized by methylation of the corresponding tributyltin precursor (2) with [(11)C]MeI in a palladium-promoted Stille cross-coupling reaction. The brain uptake of [(11)C]4 in mice peaked at 5–15 min after injection and then promptly decreased. Most radioactivity in the brain was detected in the unchanged form, although in the periphery, [(11)C]4 was rapidly metabolized to hydrophilic components. Acetazolamide (AZM) treatment significantly increased the brain uptake of [(11)C]4 without affecting the blood levels of radioactivity in mice. Preliminary kinetics analysis showed that the K(1) of [(11)C]4 reflected regional CBF in a vehicle-treated monkey, but that the K(1) did not reflect CBF in higher flow regions after AZM loading. CONCLUSION: [(11)C]4 is a potential novel CBF PET tracer. Further validation studies are needed before [(11)C]4 can be used in humans.